Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > funny when someone rises concerns re eg funding which
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(121)
•••
Comment by JMark80on Jun 11, 2020 11:53am
64 Views
Post# 31138828

RE:funny when someone rises concerns re eg funding which

RE:funny when someone rises concerns re eg funding which
edrose wrote: is far from beeing done they call us bashers  these pumpers don't want to see that r107 will take yers before we get results   they only have few results in animals  

kly as excellent phase2 in humans and our phase3  only takes one year  

WITHOUT FUNDING WITH BARDA WHICH IS NOT GUARANTEED  WE ARE GIVING AWAY 49% OF KLY TO SALZMAN FOR R107   OUR PRODUCT IS MUCH CLOSER TO GET APPROVED   

IF THE 5 MILLION PP IS SUCCESSFULL WE SHOULD NOT BUY SALZMAN

STRANGE THEY ARE NOT GIVING US UPDAE ON PP   AGAIN THIS BOARD AND CEO KEEP RETAIL INVESTORS IN THE DARK


Don't bother, Ed. You bring up legitimate concerns and don't deserve to be treated like Penny. These so-called bulls are either idiots, or being manipulative until they sell. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities